MedPath

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Phase 1
Recruiting
Conditions
B-Non Hodgkin Lymphoma
Leukemia, Lymphocytic, B Cell
B-Cell Leukemia
B-NHL
Acute Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
B-precursor ALL
B-All
Lymphoma, Non-Hodgkin
B-Cell Lymphoma
Interventions
Biological: CD19/CD22-CAR-transduced T cells
Drug: cyclophosphamide
Drug: fludarabine
Registration Number
NCT05442515
Lead Sponsor
National Cancer Institute (NCI)
Brief Summary

Background:

Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses.

Objective:

To test chimeric antigen receptor (CAR) therapy. CARs are genetically modified cells created from each patient s own blood cells. his trial will use a new type of CAR T-cell that is targeting both CD19 and CD22 at the same time. CD19 and CD22 are proteins found on the surface of most types of ALL.

Eligibility:

People aged 3 to 39 with ALL or related B-cell lymphoma that has not been cured by standard therapy.

Design:

Participants will be screened. This will include:

Physical exam

Blood and urine tests

Tests of their lung and heart function

Imaging scans

Bone marrow biopsy. A large needle will be inserted into the body to draw some tissues from the interior of a bone.

Lumbar puncture. A needle will be inserted into the lower back to draw fluid from the area around the spinal cord.

Participants will undergo apheresis. Their blood will circulate through a machine that separates blood into different parts. The portion containing T cells will be collected; the remaining cells and fluids will be returned to the body. The T cells will be changed in a laboratory to make them better at fighting cancer cells.

Participants will receive chemotherapy starting 4 or 5 days before the CAR treatment.

Participants will be admitted to the hospital. Their own modified T cells will be returned to their body.

Participants will visit the clinic 2 times a week for 28 days after treatment. Follow-up will continue for 15 years....

Detailed Description

Background:

* Despite improvements in therapy, acute lymphoblastic leukemia (ALL) contributes to significant morbidity and mortality for children and young adults with cancer. CD19-CAR and CD22-CAR therapy have proven highly effective in inducing remission in patients with relapsed/refractory disease.

* Immune escape has been observed by several groups following CD19-CAR and CD22- CAR therapy for B-ALL. Investigation of this phenomenon reveals a complex biology responsible for loss or downregulation of CD19 and/or CD22 expression observed in these cases.

* The challenges encountered with currently available CD19- and CD22-directed CAR T cells in B-ALL demonstrates the need for combinatorial treatment strategies simultaneously targeting two antigens, such as CD19 and CD22, to enhance the long-term effectiveness of CARs.

* We have previously treated patients with B-ALL on a phase 1/2 clinical trial using a bivalent CD19/22 CAR T-cell as a first combinatorial treatment strategy. This CAR T-cell construct is well-tolerated and has yielded responses however there has been limited CAR T cell expansion and persistence. Additionally, the previously tested CD19/CD22 bivalent CAR T-cell construct is limited in its ability to target CD22.

* This new CD19/22 targeted construct being tested in this clinical trial has improved dual targeting capability based on preclinical data/evaluation.

Objectives:

* Phase I: Assess the safety of administering escalating doses of autologous CD19/CD22- CAR engineered T cells in children and young adults with B cell ALL (stratified by disease burden) or lymphoma following a cyclophosphamide/fludarabine conditioning regimen.

* Phase II: Determine the efficacy of CD19/CD22 therapy in participants stratified by disease burden.

Eligibility:

-Participants between \>= 3 years and \<= 39 years of age, with CD19+/CD22+ B cell ALL or lymphoma who have relapsed or have refractory disease after at least one standard chemotherapy regimen and one salvage regimen, with no alternative curative options.

Design:

* Phase I, 3 + 3 dose escalation design across 3 cohorts (B-ALL/B-cell lymphoblastic lymphoma: A: low-disease burden (\<25 % marrow blasts without extramedullary disease) vs. B: high-disease burden (\>= 25 % marrow blasts or with EMD): C: B-cell non-Hodgkin lymphoma using the following dose levels: -2: 1 x 10\^5 transduced T cells/kg (+/- 20%); -1: 3 x 10\^5 transduced T cells/kg (+/- 20%); 1: 1 x 10\^6 transduced T cells/kg (+/- 20%); and 2: 3x 10\^6 transduced T cells/kg (+/- 20%). Cohorts will enroll concurrently.

* Participants will be treated based on disease burden and will receive 1 of 2 lymphodepleting preparative regimens:

* Lymphodepleting preparative regimen number 1: Fludarabine (30 mg/m\^2/d x 3 on Days -4, -3, -2) and cyclophosphamide (900 mg/m\^2/d x 1 on Day -2) followed by infusion of CD19/CD22-CAR T-cells on D0.

* Lymphodepleting preparative regimen #2: Fludarabine (30 mg/m2/d x 4 on Days -5, -4, -3, -2) and cyclophosphamide (600 mg/m2/d x 2 on Days -3, -2) followed by infusion of CD19/CD22-CAR T-cells on D0.

* Determination for use of LD regimen #1 versus #2 will be based on pre-treatment absolute lymphocyte count, pre-existing cytopenias, receipt of prior CAR T-cell therapy, high disease burden and assessment of infection risk.

* Participants will be evaluated sequentially for toxicity, antitumor effects, CAR expansion and persistence, and other biologic correlatives.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
116
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1/Phase I Dose Escalation-with standard LD - CLOSEDCD19/CD22-CAR-transduced T cellsCD19/CD22-CAR-transduced T cells at escalating dose + standard LD
1b/Phase 1 Dose Escalation - low disease burdenCD19/CD22-CAR-transduced T cellsCD19/CD22-CAR-transduced T cells
2/Phase I Dose Escalation- with intensified LD - CLOSEDCD19/CD22-CAR-transduced T cellsCD19/CD22-CAR-transduced T cells + standard LD
2b/Phase 1 Dose Escalation - high disease burdenCD19/CD22-CAR-transduced T cellsCD19/CD22-CAR-transduced T cells
3/Phase II Dose Expansion- with low disease burdenCD19/CD22-CAR-transduced T cellsCD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD
4/Phase II Dose Expansion- with high disease burdenCD19/CD22-CAR-transduced T cellsCD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD regimen #2
1/Phase I Dose Escalation-with standard LD - CLOSEDcyclophosphamideCD19/CD22-CAR-transduced T cells at escalating dose + standard LD
1/Phase I Dose Escalation-with standard LD - CLOSEDfludarabineCD19/CD22-CAR-transduced T cells at escalating dose + standard LD
1b/Phase 1 Dose Escalation - low disease burdencyclophosphamideCD19/CD22-CAR-transduced T cells
1b/Phase 1 Dose Escalation - low disease burdenfludarabineCD19/CD22-CAR-transduced T cells
2/Phase I Dose Escalation- with intensified LD - CLOSEDcyclophosphamideCD19/CD22-CAR-transduced T cells + standard LD
2/Phase I Dose Escalation- with intensified LD - CLOSEDfludarabineCD19/CD22-CAR-transduced T cells + standard LD
2b/Phase 1 Dose Escalation - high disease burdenfludarabineCD19/CD22-CAR-transduced T cells
2b/Phase 1 Dose Escalation - high disease burdencyclophosphamideCD19/CD22-CAR-transduced T cells
3/Phase II Dose Expansion- with low disease burdencyclophosphamideCD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD
3/Phase II Dose Expansion- with low disease burdenfludarabineCD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD
4/Phase II Dose Expansion- with high disease burdencyclophosphamideCD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD regimen #2
4/Phase II Dose Expansion- with high disease burdenfludarabineCD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD regimen #2
Primary Outcome Measures
NameTimeMethod
EfficacyMonthly until 3 months post CAR T infusion and then at 6 months and every 6 months after that, for 2 years post-infusion for each participant, up to 2 years after the entry date of the last participant.

Determine the efficacy of CD19/CD22 therapy in participants stratified by disease burden.

Safety30 days post CAR T infusion

Assess the safety of administering escalating doses of autologous CD19/CD22-CAR engineered T cells in children and young adult with B cell ALL (stratified by disease burden) or lymphoma following a cyclophosphamide/fludarabine LD.

Secondary Outcome Measures
NameTimeMethod
FeasibilityUp to two years after the last participant has entered.

Determine the feasibility of producing CD19/CD22-CAR T cells meeting the established release criteria.

Adverse Events30 days post CAR T infusion

Phase II: Assess the safety of CD19/CD22 therapy in participants based on underlying disease burden.

Persistence and expansionUp to two years after the last participant has entered.

Evaluate persistence and expansion of C19/CD22-CAR T cells in children and young adults with CD19+CD22+ B-ALL or lymphoma

Progression free survival (PFS) and Overall survival (OS)Up to two years after the last participant has entered.

Evaluate PFS and OS in participants, separately by phase II cohort

Overall response rateMonthly until 3 months post infusion and then at 6 months and every 6 months after that, for 2 years post-infusion for each participant, for up to two years from the entry date of the last participant

Phase I: Evaluate the ability of CD19/CD22-CAR T cells to mediate clinical activity in children and young adults with CD19+CD22+ B cell ALL or lymphoma.

Assess response and toxicity (CRS grade)Up to two years after last participant has entered

Assess overall response rate and CRS grades (toxicity) in participants who received subsequent infusion

Trial Locations

Locations (1)

National Institutes of Health Clinical Center

🇺🇸

Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath